OHB's Capital-Raising Hangover: A Space Champion Caught Between Dilution and Destiny

OHB SE shares fall 18% in 7 sessions despite Oddo BHF's outperform rating, as €480M capital raise triggers dilution concerns.

The German space group OHB SE is living through a peculiar kind of contradiction this week. A freshly minted "Outperform" rating from Oddo BHF, complete with a €290 price target, has done nothing to arrest a slide that has now wiped 18 percent off the share price in just seven trading sessions. The stock changed hands at €194.80 on Wednesday, roughly 1.1 percent below Tuesday's close of €197.00.

The disconnect is stark enough to make even seasoned investors pause. Oddo's Stephane Beyazian called OHB "the best European option in the race into space," pointing to the planned SpaceX listing and US government expansion plans as sector accelerants. Yet the market is preoccupied with something far more mechanical: the digestion of a freshly completed capital increase.

The €480 Million Question

The capital raise, which drew subscriptions from over 200 investors, was designed to fund production capacity, potential acquisitions and the expansion of the launch-vehicle business. But the mechanics of the deal have left a sour taste. Roughly 94 percent of the new shares were placed with targeted investors, yet several cornerstone shareholders—including the Fuchs family and private equity firm KKR—chose to waive their subscription rights. The new shares began trading below their issue price, an early signal that the market is weighting dilution more heavily than operational growth.

That decision by long-standing investors can be read in two ways. Optimists see it as a pragmatic move by holders who simply didn't want to increase exposure at current levels. Skeptics view it as a quiet vote of no-confidence in the valuation. Either way, the sheer volume of new paper hitting the market is exerting a gravitational pull on the share price that no analyst endorsement can counteract.

A Company Out of Sync With Its Own Stock

The operational picture, meanwhile, tells a different story. When OHB reported first-half results on August 6, revenue came in at €627.9 million—an 11 percent year-on-year improvement—with an order backlog of roughly €3.3 billion. Management reaffirmed full-year guidance of €1.4 billion in total output and an adjusted EBITDA margin between 10.5 and 11.0 percent.

None of that has stopped the stock from falling 72 percent below its May high of €688.00. The current price sits 27 percent below the 50-day moving average and 24 percent below the 200-day average—a technical picture that resembles a stock in full distribution rather than one with a growing backlog and confirmed guidance. The relative strength index at 29.8 points to oversold conditions, while annualized volatility of 61 percent underscores just how jittery trading in the name has become.

Beyond the Balance Sheet

Amid the noise around financing and share structure, OHB continues to make quiet progress on the kind of projects that define its long-term strategic value. The company announced that its "EasyMotion-2" training suit has been qualified for experiments aboard the International Space Station. The device is designed to study how muscle atrophy can be prevented in zero gravity—one of the most significant physiological hurdles to long-duration spaceflight, whether aboard the ISS, future orbital stations or missions to the Moon.

It is a small detail in the broader picture, but a telling one. OHB increasingly positions itself as a systems provider spanning the full spectrum of space activity, from satellite construction to life-support systems. That breadth is likely one reason institutional investors have held their positions despite the correction. The low free float, combined with speculation about further capital measures, is probably doing more to drive the current downtrend than any operational news flow.

Two Speeds, One Direction?

The central tension is whether the market's short-term focus on financing questions will eventually give way to the longer-term narrative of a company building the infrastructure for the next generation of space exploration. The answer hinges on how quickly the market absorbs the newly issued shares. Until that digestion is complete, pure supply will keep pressing on the price, regardless of how convincing the operational story looks.

Should sentiment turn—perhaps on concrete progress toward the SpaceX listing, additional positive analyst commentary, or visible deployment of the fresh capital into new contracts—the €290 target could come into reach faster than the current chart suggests. For now, the technical selling pressure from the capital increase remains the dominant force, and investors would be wise to watch whether institutional selling continues or finally abates. That, more than any single announcement, will determine the next leg of the journey.